Investigating B7-H4's Role in Glioma Vaccine Response
The Role and Mechanism of B7-H4/ATF3 Axis From Glioma Associated Macrophages in Treatment Resistance of Cancer Vaccine
Huashan Hospital · NCT06156150
This study is trying to see how a protein called B7-H4 affects the response to cancer vaccines in people with glioma to help find better treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Huashan Hospital (other) |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06156150 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on glioma patients to explore the role of B7-H4 in the resistance to therapeutic cancer vaccines. It aims to understand how B7-H4 overexpression in macrophages correlates with decreased T cell infiltration and vaccine efficacy. By analyzing tissue samples from glioma patients, the study seeks to uncover the mechanisms behind vaccine resistance, potentially leading to improved treatment strategies. The research is conducted at Huashan Hospital, where eligible patients will provide informed consent for participation.
Who should consider this trial
Good fit: Ideal candidates are glioma patients aged 18-80 who can provide tissue samples for analysis.
Not a fit: Patients currently participating in other clinical trials or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to enhanced therapeutic strategies for glioma patients by overcoming vaccine resistance.
How similar studies have performed: While the approach of investigating B7-H4 in the context of glioma vaccine resistance is novel, previous studies have shown that targeting immune checkpoints can improve cancer treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Inclusion Criteria: The patients with glioma in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled 1. They were 18-80 years old, male and female; 2. The pathological results of frozen section during operation were gliomas; 3. Tissue (6 mm \* 6 mm) can be used for cell sorting on the basis of not affecting clinical routine diagnosis; 4. Sign informed consent. Exclusion Criteria: Patients who meet any of the following criteria will not be included in this study: 1. Participants in other clinical trials; 2. Pregnant women.
Where this trial is running
Shanghai, Shanghai Municipality
- Di Chen — Shanghai, Shanghai Municipality, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glioma, glioma, treatment resistance, immunotherapy, cancer vaccine, macrophage